middle.news
How Is Dimerix Advancing DMX-200 Amid Rising Losses?
9:48am on Thursday 26th of February, 2026 AEDT
•
Healthcare
Read Story
How Is Dimerix Advancing DMX-200 Amid Rising Losses?
9:48am on Thursday 26th of February, 2026 AEDT
Key Points
Net loss increased 24% to $15.97 million
R&D expenditure nearly doubled to $21.3 million
License income jumped 388% to $2.1 million
DMX-200 Phase 3 trial in FSGS completed recruitment of 286+ patients
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
DIMERIX (ASX:DXB)
OPEN ARTICLE